Cargando…

Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, affected by both genetics and environment. Type 2 diabetes (T2D) stands as an independent environmental risk factor that precipitates the onset of hepatic steatosis and accelerates its progression to severe stages of live...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ziqi, Ji, Guang, Li, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497960/
https://www.ncbi.nlm.nih.gov/pubmed/37711901
http://dx.doi.org/10.3389/fendo.2023.1247611
_version_ 1785105417238478848
author Zhang, Ziqi
Ji, Guang
Li, Meng
author_facet Zhang, Ziqi
Ji, Guang
Li, Meng
author_sort Zhang, Ziqi
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, affected by both genetics and environment. Type 2 diabetes (T2D) stands as an independent environmental risk factor that precipitates the onset of hepatic steatosis and accelerates its progression to severe stages of liver damage. Furthermore, the coexistence of T2D and NAFLD magnifies the risk of cardiovascular disease synergistically. However, the association between genetic susceptibility and metabolic risk factors in NAFLD remains incompletely understood. The glucokinase regulator gene (GCKR), responsible for encoding the glucokinase regulatory protein (GKRP), acts as a regulator and protector of the glucose-metabolizing enzyme glucokinase (GK) in the liver. Two common variants (rs1260326 and rs780094) within the GCKR gene have been associated with a lower risk for T2D but a higher risk for NAFLD. Recent studies underscore that T2D presence significantly amplifies the effect of the GCKR gene, thereby increasing the risk of NASH and fibrosis in NAFLD patients. In this review, we focus on the critical roles of GKRP in T2D and NAFLD, drawing upon insights from genetic and biological studies. Notably, prior attempts at drug development targeting GK with glucokinase activators (GKAs) have shown potential risks of augmented plasma triglycerides or NAFLD. Conversely, overexpression of GKRP in diabetic rats improved glucose tolerance without causing NAFLD, suggesting the crucial regulatory role of GKRP in maintaining hepatic glucose and lipid metabolism balance. Collectively, this review sheds new light on the complex interaction between genes and environment in NAFLD, focusing on the GCKR gene. By integrating evidence from genetics, biology, and drug development, we reassess the therapeutic potential of targeting GK or GKRP for metabolic disease treatment. Emerging evidence suggests that selectively activating GK or enhancing GK-GKRP binding may represent a holistic strategy for restoring glucose and lipid metabolic balance.
format Online
Article
Text
id pubmed-10497960
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104979602023-09-14 Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD Zhang, Ziqi Ji, Guang Li, Meng Front Endocrinol (Lausanne) Endocrinology Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, affected by both genetics and environment. Type 2 diabetes (T2D) stands as an independent environmental risk factor that precipitates the onset of hepatic steatosis and accelerates its progression to severe stages of liver damage. Furthermore, the coexistence of T2D and NAFLD magnifies the risk of cardiovascular disease synergistically. However, the association between genetic susceptibility and metabolic risk factors in NAFLD remains incompletely understood. The glucokinase regulator gene (GCKR), responsible for encoding the glucokinase regulatory protein (GKRP), acts as a regulator and protector of the glucose-metabolizing enzyme glucokinase (GK) in the liver. Two common variants (rs1260326 and rs780094) within the GCKR gene have been associated with a lower risk for T2D but a higher risk for NAFLD. Recent studies underscore that T2D presence significantly amplifies the effect of the GCKR gene, thereby increasing the risk of NASH and fibrosis in NAFLD patients. In this review, we focus on the critical roles of GKRP in T2D and NAFLD, drawing upon insights from genetic and biological studies. Notably, prior attempts at drug development targeting GK with glucokinase activators (GKAs) have shown potential risks of augmented plasma triglycerides or NAFLD. Conversely, overexpression of GKRP in diabetic rats improved glucose tolerance without causing NAFLD, suggesting the crucial regulatory role of GKRP in maintaining hepatic glucose and lipid metabolism balance. Collectively, this review sheds new light on the complex interaction between genes and environment in NAFLD, focusing on the GCKR gene. By integrating evidence from genetics, biology, and drug development, we reassess the therapeutic potential of targeting GK or GKRP for metabolic disease treatment. Emerging evidence suggests that selectively activating GK or enhancing GK-GKRP binding may represent a holistic strategy for restoring glucose and lipid metabolic balance. Frontiers Media S.A. 2023-08-29 /pmc/articles/PMC10497960/ /pubmed/37711901 http://dx.doi.org/10.3389/fendo.2023.1247611 Text en Copyright © 2023 Zhang, Ji and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Ziqi
Ji, Guang
Li, Meng
Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title_full Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title_fullStr Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title_full_unstemmed Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title_short Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
title_sort glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in nafld
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497960/
https://www.ncbi.nlm.nih.gov/pubmed/37711901
http://dx.doi.org/10.3389/fendo.2023.1247611
work_keys_str_mv AT zhangziqi glucokinaseregulatoryproteinabalancingactbetweenglucoseandlipidmetabolisminnafld
AT jiguang glucokinaseregulatoryproteinabalancingactbetweenglucoseandlipidmetabolisminnafld
AT limeng glucokinaseregulatoryproteinabalancingactbetweenglucoseandlipidmetabolisminnafld